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Abstract
Pulmonary hypertension (PHTN) is a rare and devastating disease characterized by progressive increases in pulmonary arterial
pressure and pulmonary vascular resistance, which eventually leads to right ventricular failure and death. At present there is no
cure for pulmonary arterial hypertension (PAH); however over the past decade targeted pharmaceutical options have become
available for the treatment of PAH. Prior to evaluation for therapeutic options a definitive diagnosis of pulmonary arterial hypertension must be made via comprehensive physical exam and definitive diagnostic testing. Screening test of choice remains
echocardiography and gold standard for definitive diagnosis is right heart catheterization. Once the establishment of a diagnosis
of PAH is made therapeutic options may be a possibility based on a diagnostic algorithm and disease severity of the PAH patient.
There are different classes of medications available with different mechanisms of actions which have a vasodilatory effect and
improve exercise tolerance, quality of life as well as survival.
Key words: pulmonary arterial hypertension, phosphodiesterase type 5 inhibitors, endothelin receptor antagonist, prostacyclin
analogues, right heart catheterization
Pneumonol Alergol Pol 2016; 84: 47–61

Introduction
Pulmonary hypertension (PHTN) is a rare and
devastating disease characterized by progressive
increases in pulmonary arterial pressure and pulmonary vascular resistance which eventually leads
to right ventricular failure and death [1]. Symptomatically it is characterized by increasing shortness of breath and worsening exercise tolerance.
It may due to various etiologies such as left heart
disease, parenchymal lung disease, chronic thromboembolic disease, hematologic disorders or it may
be idiopathic in nature though the clinical picture
of these patients is similar [2]. More specifically
pulmonary arterial hypertension (PAH) is due to
direct injury to the pulmonary vessels and vascular
bed. At present there is no cure for PAH, however
over the past decade targeted pharmaceutical

options have become available for the treatment
of PAH. There are different classes of medications
available with different mechanisms of actions all
which net a vasodilatory and anti-proliferative
effect. These medications provide improvement in
exercise tolerance, pulmonary hemodynamics and
quality of life. This review will attempt to outline
all the current treatment options for subject with
PAH including new drugs that are on the horizon
as based on newly published European Respiratory
Society (ERS) and European Society of Cardiology
(ESC) guidelines on the diagnosis and treatment
of pulmonary hypertension [3].

Classification and diagnosis
Pulmonary hypertension (PHTN) is defined
hemodynamically as a mean resting pulmonary
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Table 1. World Health Organization’s Classification of Pulmonary Hypertension — Nice [modified from 2]
Group I — Pulmonary arterial hypertension
Idiopathic PAH
Heritable (BMPR2, ALK1, Endoglin, Unknown)
Familial disorder
Related conditions
		
Collagen vascular disease (Scleroderma)
		
Congenital systemic-to-pulmonary shunt
		
Portal hypertension
		
Human immunodeficiency virus infection
		 Schistosomiasis
		
Drugs and toxins (Aminorex ,Fenfluramine ,Dexfenfluramine)
Pulmonary veno-occlusive disease
Persistent pulmonary hypertension of the newborn
Group II — Pulmonary venous hypertension
Systolic dysfunction
Diastolic dysfunction
Valvular disease
Group III — Pulmonary hypertension associated with disorders of the respiratory system and/or hypoxemia
Chronic obstructive pulmonary disease
Interstitial lung disease
Sleep-disordered breathing
Alveolar hypoventilation disorders
Chronic exposure to high altitudes
Neonatal lung disease
Group IV — Pulmonary hypertension resulting from chronic thrombotic and/or embolic disease (CTEPH)
Group V — Pulmonary hypertension with unclear multifactorial mechanisms
Hematologic diseases: myeloproliferative disease, splenectomy
Systemic diseases: sarcoidosis, Langerhans cell histiocytosis: neurofibromatosis, vasculitis
Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid diseases

artery pressure (mPAP) greater than or equal 25
mm Hg. The World Health Organization (WHO)
has proposed a classification system for pulmonary hypertension based on common clinical
features and etiology which has been outlined
in Table 1 [2]. Pre-capillary pulmonary hypertension which encompasses pulmonary arterial
hypertension (PAH) (WHO Group I), PHTN due to
primary lung disease (WHO Group III), Chronic
Thromboembolic PHTN (WHO Group IV) and
PHTN with an unclear or multifactorial etiology
(WHO Group V), is defined as a mPAP greater
than or equally to 25 mm Hg as well as a pulmonary artery wedge pressure (PAWP) less than or
equal to 15 mm Hg which must be confirmed by
right heart catheterization (RHC) [3]. Pulmonary
vascular resistance (PVR) has also been added to
the definition of PAH. Definitions of PHTN, PAH
and subgroups of PHTN have been outlined in
Table 2 [3].

Pharmacological management
Once the establishment of a diagnosis of
PAH is confirmed via RHC, therapeutic options
may be a possibility based on an algorithm (Fig.
48

1) and PAH disease risk stratification outlines in
Table 3. In PAH, the pulmonary vasculature is
the exclusive target of disease. The pathologic
vasoconstriction and inflammatory vascular remodeling associated with PAH is a prominent feature leading to the rationale for using pulmonary
vasodilators therapies and now options are many.
The pathophysiology of PAH lies within endothelial dysfunction which leads to an imbalance of
vasodilator and vasoconstrictor mediators ultimately resulting in vasoconstriction. In addition
dysfunction of the endothelium leads to release
of pro-inflammatory mediators. The elucidation
of molecules involved in the regulation of pulmonary vasculature has led to the development
of currently approved PAH therapies, which all
target one of the following key pathways: (1)
prostacyclin (PGI2), (2) nitric oxide (NO), and (3)
endothelin-1 (ET-1) pathways shown in Figure 2.
Treatment goals in the setting of PAH are
focused on the improvement of both hemodynamic parameters and exercise tolerance, resulting
in increased survival. Commonly evaluated
parameters include: WHO functional class (FC),
hemodynamic parameters, mainly right atrial
pressure, cardiac index and mixed venous oxy-
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Table 2. Hemodynamic definitions of pulmonary hypertension [3]
Definition

Hemodynamics

Clinical Subgroup

Pulmonary Hypertension (PHTN)

mPAP ≥ 25 mm Hg

All types of PHTN

Pre-capillary PHTN

mPAP ≥ 25 mm Hg
PCWP ≤ 15 mm Hg

WHO Group I — Pulmonary arterial hypertension
WHO Group III — PHTN due to lung disease
WHO Group IV — Chronic thromboembolic PHTN
WHO Group V — PHTN due to unclear and/or multifactorial etiology

Post-capillary PHTN

mPAP ≥ 25 mm Hg
PCWP > 15 mm Hg

WHO Group II — PHTN due to left heart disease
WHO Group V — PHTN due to unclear and/
/or multifactorial etiology

Isolated post-capillary PHTN
Combined post-capillary and precapillary PHTN

DPG < 7 mm Hg and/or PVR ≤ 3 WU
DPG ≥ 7 mm Hg and/or
PVR > 3 WU

mPAP — mean pulmonary arterial pressure; PCWP — pulmonary capillary wedge pressure; DPG — diastolic pressure gradient (diastolic PAP — mean PCWP); PVR
— pulmonary vascular resistance; WU — wood units

Figure 1. Treatment algorithm for pulmonary arterial hypertension patients; CCG — calcium channel blockers

gen saturation, right atrial area and pericardial
effusion presence on echocardiography, distance
covered on 6 minute walk test (6MWT), peak VO2
on cardiopulmonary exercise testing and B-type
natriuretic peptide (BNP) levels. Goals of PAH
therapy have been outlined in Table 4 [4].
The following section will serve to outline
general measures and pharmaceutical options

that exist in the treatment of PAH. The European Respiratory Society has put forth Classes of
Recommendation as well as Levels of Evidence
to determine what therapies are most efficacious
based on evidence in the literature which have
been reflected in the presented tables [3]. Classes of recommendations are as follows: Class I:
Evidence and/or general agreement that a given
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Table 3. Risk Stratification of PAH Patients based on ERS Guidelines [3]
Low Risk

Intermediate Risk

High Risk

Clinical signs of right heart failure

No

No

Yes

Symptom progression

No

Gradual

Rapid

Syncope

No

Occasional

Repeated

WHO functional class

I, II

III

IV

> 440 m

165−440 m

< 165 m

NT-proBNP Plasma levels

BNP < 50 ng/l
NT-proBNP < 300 ng/ml

BNP 50−300 ng/l
BT-proBNP 300−1400 ng/l

BNP > 300 ng/l
BT-proBNP > 1400 ng/l

CPET peak VO2

Peak VO2 > 15 ml/min/kg

Peak VO2 11−15 ml/min/kg

Peak VO2 < 1 ml/min/kg

RA are < 18 cm2
No pericardial effusion

RA area 18−26 cm2
No or minimal pericardial effusion

RA are > 26 cm2 Pericardial effusion

RAP < 8 mm Hg
CI ≥ 2.5 l/min/m2

RAP 8−14 mm Hg
CI 2.0−2.4 l/min/m2

RAP > 14 mm Hg
CI < 2.0 l/min/m2

Clinical Determinant

6MWD

Echocardiography Findings
Hemodynamics

6MWD — 6-minute walk distance; BNP — brain natriuretic peptide; CI — cardiac index; NT-proBNP – n-terminal brain natriuretic peptide; RA — right atrium; RAP
— right atrium pressure; VO2 — oxygen consumption

cAMP — cyclic adenosine monophosphate; cGMP — cyclic guanosine monophosphate; ET — endothelin receptor; GTP — guanosine triphosphate; PDE5 — cGMP
-specific phosphodiesterase type 5; PgI2 — prostacyclin; sGC — soluble guanylate cyclase

Figure 2. Mechanism of action and rationale of approved PAH therapies

treatment or procedure is beneficial, useful and
effective; Class II: Conflicting evidence and/or
a divergence of opinion about the given favor
of usefulness/efficacy of the given treatment or
procedure: Class IIa: Weight of evidence/opinion
is in favor of usefulness/efficacy; Class IIb: Usefulness/efficacy is less well established by evidence/
opinion; Class III: Evidence or general agreement
that the given treatment or procedure is not useful/effective, and in some cases may be harmful.
Levels of evidence are as follows: Level of evi50

dence A: Data derived from multiple randomized
clinical trials or meta-analysis; Level of evidence
B: Data derived from a single randomized trial or
large non-randomized studies; Level of evidence
C: Consensus of opinion of the experts and/ or
small studies, retrospective studies, registries [3].

General measures and non-specific therapies
General measures can be applied to all patients found to have PAH; Recommendations set
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Table 4. Goals of PAH specific therapy (adapted from [4])
Functional class

I or II

Echocardiography/cardiac magnetic resonance

normal/near normal RV size and function
RAP, 8 mm Hg; CI 2.5 to 3.0 L/min/m2

Hemodynamics
6-min walk distance

> 330 to 440 meters may not be aggressive enough in young
individuals

Cardiopulmonary exercise testing

Peak VO2 > 15 ml/min/kg ; EQCO2 <45 l/min/l/min

B-type natriuretic peptide level

normal

CI — cardiac index; RAP — right atrial pressure; RV — right ventricle

Table 5. Recommendations for General Measures [3]
Recommendations

Class

Level

Pregnancy is contraindicated in PAH

I

C

PAH patients should be immunized against influenza and pneumococcal infection

I

C

Psychosocial support is recommended in PAH patients

I

C

Supervised exercise training should be considered in PAH therapy under medical therapy

IIa

B

In elective surgery, epidural rather than general anesthesia should be used

IIa

C

Excessive physical activity that leads to distressing symptoms should be avoided in PAH patients

III

C

Table 6. Recommendations for Supportive Pharmacotherapy [3]
Class

Level

Continuous long term oxygen therapy is recommended in PAH patients when oxygen press is less than 60 mm Hg

Recommendations

I

C

Diuretic treatment in PAH patients with evidence of right ventricular failure and fluid retention

I

C

Oral anticoagulant use in patients with idiopathic or heritable PAH and PAH due to anorexigen use

IIb

C

Correction of anemia and/or iron status in PAH patients

IIb

C

forth by the ERS have been outlined in Table
5. In addition to above-mentioned supportive
measures, some pharmacotherapy may be used
in conjunction with PAH specific therapies.
Continuous long-term oxygen therapy should be
initiated in patients who are not able to maintain
adequate oxygen saturation (PaO2 less than 60
mm Hg) [5]. In general patients found to have
PAH should adhere to a low sodium diet to avoid
volume overload and the careful use of diuretics
can be helpful in reducing volume and right heart
strain [6]. Care should be taken to avoid excessive
diuresis to avoid reduction of cardiac output. It
has also been suggested that PAH patients are at
risk for in situ thrombosis of altered pulmonary
vessels which may contribute to disease progression and it has been proposed that therapeutic
anticoagulation might have beneficial effects
[7]. Recently concluded COMPERA registry has
provided further proof of survival advantage for

patients with idiopathic PAH, heritable PAH and
drug induced PAH treated with anticoagulants,
suggesting that these patients benefit from therapeutic anticoagulation. The situation remains
inconclusive for patients with other forms of PAH
for whom no therapeutic effect of anticoagulation was detectable [8]. In addition a study has
shown that correction of anemia or optimization
of iron status may be beneficial in the setting of
PAH [9]. Recommendations for the use of support
pharmacotherapy has been shown in Table 6.
After general measures are initiated PAH specific therapies may be initiated which have been
described below.

Calcium channel blockers

For a select group of pulmonary hypertension
patients, which include only idiopathic PAH, heritable PAH or drug-induced PAH patients, high
dose calcium channel blocker (CCB) therapy may
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Table 7. Recommendations on the use of Prostacyclin Analogues (adapted from Galie at al. [3])
Treatment

Class and Level of Recommendation
WHO FC II

Epoprostenol
Iloprost
Treprostinil

Beraprost*

References

WHO FC III

WHO FC IV

Intravenous

–

–

I

A

I

A

[14, 15]

Inhaled

–

–

I

B

IIB

C

[21]

Intravenous*

–

–

IIa

C

IIB

C

[60]

Subcutaneous

–

–

I

B

IIB

C

[17]

Inhaled*

–

–

I

B

IIB

C

[18]

Intravenous

–

–

IIa

C

IIB

C

[19]

Oral*

–

–

II

B

–

–

[20]

–

–

IIb

B

–

–

[61]

*Not approved by European Medicine Agency (EMA) at time of ERS Guidelines publication [3]

be an option. To determine if CCBs are a viable
option for such patients, pulmonary vasoreactivity testing for identification of patients is recommended at time of RHC [3]. Acute vasoreactivity
is performed with the use of inhaled nitric oxide
(NO) at 10–20 parts per million (ppm) but i.v. epoprostenol, i.v. adenosine or inhaled iloprost can
be used as alternatives. A positive acute response
is defined as a reduction of the mean PAP ≥ 10
mm Hg to reach an absolute value of mean PAP
≤ 40 mm Hg with an increased or unchanged CO.
Only about 10% of patients with idiopathic PAH
will meet these criteria [10, 11]. In patients who
show evidence of an acute hemodynamic response to selective vasodilators during RHC, long-term
treatment with CBB, administered orally in high
dosages, can produce a sustained hemodynamic
response and increase survival [12]. Comparison
of responders to acute vasoreactivity testing with
the remaining PAH patients revealed that they
had less severe disease at baseline. During acute
vasodilator testing, long-term CCB responders
displayed a more pronounced fall in mean PAP
and after 7.0 ± 4.1 years, all but 1 long-term CCB
responders were alive in NYHA class I or II, with
a sustained hemodynamic improvement. In the
group of patients who failed on CCB, the 5-year
survival rate was 48% [10].

Prostacyclin analogues
Released by the endothelial cells’ prostacyclin I2 (PGI2) is a potent pulmonary vasodilator,
exerting its effects via adenylate cyclase. The
other mechanisms of action are: the inhibition
of platelet aggregation and anti-proliferative
effect. Epoprostenol is a PGI2 derivative which
has been shown to improve exercise capacity,
52

quality of life, hemodynamics and long-term
survival in PAH patients [13, 14]. Demonstrative
trial of epoprostenol showed that patient with
PAH classified as NYHA functional class III or IV
were randomized to receive either conventional
therapy alone (warfarin, diuretics, oxygen, and
oral vasodilators) or conventional therapy and
epoprostenol. Patients in the epoprostenol group
had functional improvement, 6MWD (362 m at
12 weeks vs. 315 m at base line) and a decrease
in mPAP and pulmonary vascular resistance [15].
There exists also a thermostable form of epoprostenol that lessens its burden of use and may
improve patient compliance [16].
Treprostinil is a prostacyclin analogue that
has also been successful in treating PAH by
improving exercise capacity, functional class,
hemodynamics and quality of life [17]. It exists
in injectable form as well as a continuous subcutaneous infusion. A double-blind, placebocontrolled multicenter trial in PAH showed that
exercise tolerance improved (median change of
+10 m (−24 to 47 m; 25th–75th percentile) while
unchanged in the placebo (median change of 0
m (−44 to 32 m; 25th–75th percentile). It was also
seen that, treprostinil significantly improved
indices of dyspnea, signs and symptoms of pulmonary hypertension, and hemodynamics [17].
Of note is the fact that there may be site pain at
insertion of subcutaneous catheter. Inhaled [18]
and intravenous [19] treprostinil are also options
for class II and IV patients. More recently an oral
form of treprostinil has been approved as a first
line therapy for patients exhibiting functional
class III symptoms [20].
Inhaled iloprost has also been shown to induce vasodilatation lasting up to 60−120 minutes and has been shown to improve the dyspnea
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Table 8. Recommendations on the use of Endothelin Receptor Antagonists (adapted from Galie at al. [3])
Treatment

Class and Level of Recommendation
WHO FC II

References

WHO FC III

WHO FC IV

Ambrisentan

I

A

I

A

IIb

C

[25−27]

Bosentan

I

A

I

A

IIb

C

[17, 22−24, 42]

Macitentan

I

B

I

B

IIb

C

[30]

scores and hemodynamic variables but the major
limitation was the repetitive inhalation 6−9 times
daily [21]. A randomized, multicenter, placebocontrolled trial involving patients from WHO
function class III or IV with PAH used as a combined end point a 10 percent increase in patients’
scores on a six-minute walk test and improvement
in NYHA functional class [21]. Seventeen percent
of treated patients reached this end point, as compared with 4 percent of the placebo group. There
was a gain of 59 m on 6MWD among patients with
PAH. Side effects included cough and symptoms
linked to systemic vasodilatation. In addition,
syncope was more frequent in the iloprost group
than in the placebo group. Recommendations
have been presented in Table 8.

Endothelin pathway (endothelin receptor
antagonists (ERA))
Endothelin1 (ET-1) is a potent vasoconstrictor
and increased levels of ET-1 in vascular endothelial cells and in plasma has been demonstrated in
patients with PAH which serves as the rationale
for the ERAs. Bosentan was the first ERA approved
by the Food and Drug Administration (FDA) for
the management of PAH for use in patients with
PAH associated with FC II–IV symptoms [22, 23].
Initial studies on WHO Functional Class III scleroderma related PAH patients showed that in the
bosentan group 6MWD and cardiac index significantly improved and that pulmonary vascular
pulmonary vascular resistance decreased. Patients
given bosentan also experienced a reduction of
Borg dyspnea index and an improved WHO functional class [24]. Efficacy was further confirmed
by the subsequent BREATHE-1 (Bosentan Randomized Trial of Endothelin Antagonist Therapy)
trial [17] in which PAH patients who were NYHA
functional classes III and IV showed improvement
in WHO functional class and the prolongation of
time to clinical worsening. Increases in liver aminotransferases greater than 8 times the upper limit
of normal were again noted in the bosentan group
and were dosage-dependent: with 2 patients in

the 125-mg group and 5 patients in the 250-mg
group [17]. Bosentan was also studied in NYHA
functional class II patients and has demonstrated
positive outcomes in this group of patients [23].
Ambrisentan is a highly selective ET-A antagonist with a long half-life to allow once daily
dosing that has been approved for PAH functional classes II and III. Data from two studies have
shown that ambrisentan taken over 12 weeks
significantly improved 6MWD in PAH patients.
Associated extension study data also confirmed
that continuation of treatment for two years
was associated with sustained improvements in
exercise capacity and a reduced risk of clinical
worsening and death [25]. After demonstrating a
favorable safety and efficacy profile in an initial
dosing study [26] showing improvement in pulmonary hemodynamics two randomized controlled trials, ARIES-1 and ARIES-2 (ARIES-1, 5 mg,
10 mg, placebo; ARIES-2, 2.5 mg, 5 mg, placebo)
were conducted [27]. Both trials showed improvement in 6MWD and in the ARIES-2 trial, there
was a significant improvement in time to clinical
worsening. Improvement in WHO functional class
was found to be significant in the ARIES-1 trial
and it was observed in the ARIES-2 trial, but again
it was not found to be statistically significant.
Macitentan is the newest Food and Drug
Administration (FDA) approved tissue-targeting
ERA that has been shown to significantly decrease
the risk of a morbidity and mortality event over
the treatment period, and improved 6MWD and
NYHA FC [28]. Macitentan is a tissue targeting
endothelin receptor blocker that inhibits binding
of ET-1 to receptors ET-A and ET-B that has been
FDA approved for NYHA Class II-III pulmonary
arterial hypertension. Macitentan is a lipophilic sulfamide compound designed to decrease
vascular resistance by exhibiting enhanced tissue
penetration and prolonged receptor binding to
ET-A/ET-B in pulmonary arterial smooth muscle
cells [29].
A long term randomized, controlled study
(SERAPHIN) was conducted. The study was
intended to determine safety and efficacy of
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macitentan until the first sign of clinical worsening and all-cause mortality in patients with
symptomatic pulmonary arterial hypertension.
Patients were on Macitentan therapy up to 42
months and a total of 250 patients were randomly
assigned to placebo, 250 patients to macitentan
3 mg once-daily, and 242 to macitentan 10 mg
daily. Macitentan, at both the 3 mg and 10 mg
doses met primary endpoints, decreasing the risk
of a morbidity/mortality over the treatment period
versus placebo [30].
This risk was found to be reduced by 45%
in the 10 mg dose group (p < 0.0001) and the
3 mg group showed a risk reduction of 30% (p
= 0.01). Secondary endpoints included 6MWD
change in the first 6 months of therapy as well as
NYHA functional class and time to either death
or hospitalization due to PAH. These endpoints
also showed a dose dependent effect (p < 0.05
for either dose) [30].
Adverse events and discontinuation of treatment due to adverse events was similar across all
groups. Adverse events associated with macitentan were headache, nasopharyngitis, and anemia.
Elevations of liver aminotransferases greater
than three times the upper limit of normal were
observed in 4.5% of patients receiving placebo,
in 3.6% of patients on 3 mg of macitentan and in
3.4% of patients on 10 mg of macitentan [30]. Recommendations have been presented in Table 8.

Nitric Oxide Pathway (Phosphodiesterase 5
Inhibitors)
Nitric Oxide (NO) is a short acting endogenous molecule that plays a key role for controlling
vascular smooth muscle tone that results in vasodilatation and inhibiting proliferation. NO diffuses through cells and activates soluble guanylate
cyclase leading to an increase in cyclic guanosine
3’−5’ monophosphate (cGMP) resulting in smooth
muscle relaxation. The enzyme PDE-5 inhibitors
are abundantly expressed in high concentration in
the lungs, platelets and vascular smooth muscle
and are responsible for degradation of cGMP [31].
At the level of the endothelium nitric oxide
indirectly acts as a potent vasodilator by upregulating the production of cyclic guanosine monophosphate (cGMP). Phosphodiesterase type 5
(PDE-5) is an enzyme that degrades cGMP leading
to vasoconstriction [31]. Sildenafil, the first PDE-5
inhibitor approved for PAH is indicated for patients with FC II-III symptoms. Patients that are
on this medication have shown improvement in
symptoms, 6MWD as well as FC [26]. Clinical
54

research studies have found sildenafil to improve
pulmonary hemodynamic and exercise capacity
in PAH patients.
Initially a double blinded, placebo-controlled, cross over study of 22 patients randomized
to receive sildenafil or placebo for 6 weeks and
then crossed over with a primary endpoint of
exercise tolerance demonstrated clinical efficacy
[32]. Patients on sildenafil showed significant
improvement in exercise time while the placebo
arm showed a decrease in exercise tolerance.
Other improvements noted were cardiac index
assessed by echocardiography along with dyspnea and fatigue components of QoL, however no
significant improvement was seen in estimated
pulmonary artery systolic pressure (PASP) [32].
The trial that demonstrated clinical efficacy
of sildenafil was the SUPER-1 trial [33]. The SUPER-1 trial was a double blind, multi- center, placebo controlled study of 278 PAH patients. PAH
symptomatology was either idiopathic, associated
with connective tissue disease or with repaired
congenital systemic to pulmonary shunts. Most
patients belonged to WHO functional class II
(39% of patients) or III (58% of patients). Patients
were randomized to receive placebo or sildenafil
20 mg, 40 mg or 80 mg three times daily for 12
weeks. The primary endpoint of the study was to
monitor for change in distance walked in 6 minutes from baseline to 12 weeks. By the end of 12
weeks, there was significant improvement in walk
distance of 45 m, 46 m and 50 m in all three dose
regimens of 20 mg, 40 mg and 80 mg, respectively.
Sildenafil was found to improve exercise capacity
in all three groups over placebo. The study also
noted a significant improvement in hemodynamic measurements such as mPAP, cardiac index
and PVR. There was also improvement change
in functional class, with no significant delay in
time to clinical worsening or Borg Dyspnea Index
(BDI) [33].
Tadalafil is the second PDE-5 inhibitor to be
approved for PAH WHO Group 1 patients. The
first large scale trial to study the efficacy of Tadalafil was the PHIRST study [34]. The study was a
16 weeks double blinded, placebo controlled and
multi-centered study of 405 patients (WHO Group
1, FC II or III) who were either on bosentan or one
of five treatment arms. Patients were randomized
into once daily dosing of 2.5 mg, 10 mg, 20 mg,
40 mg or a placebo group. The primary endpoint
of study was to detect any change in 6MWD from
baseline. Along with 6MWD, secondary endpoints
measured were WHO FC, hemodynamic changes,
Borg dyspnea scale and quality of life. It was fo-
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Table 9. Recommendations on the use of Phosphodiesterase 5 Inhibitors (adapted from Galie at al. [3])
Treatment

Class and Level of Recommendation
WHO FC II

References

WHO FC III

WHO FC IV

Sildenafil

I

A

I

A

IIb

C

[32, 33]

Tadalafil

I

B

I

B

IIb

C

[34]

IIb

B

IIb

B

IIb

C

[51]

Vardenafil*

*Not approved by European Medicine Agency (EMA) at time of ERS Guidelines publication [3]

und the tadalafil group showed an improvement
in 6MWD. There was also reduced incidence of
clinical worsening, fewer hospitalizations and
showed significant improvement, in health related QoL, No improvement was observed in Borg
dyspnea score or WHO classification for any given
treatment arm, which was a consistent finding
with other studies as well. Recommendations
have been presented in Table 9.

Soluble guanylate cyclase (sGC)
stimulator

Riociguat is a direct sGC stimulator that is
the only therapy approved by the Food and Drug
Administration. Riociguat stabilizes NO-soluble
guanylate cyclase coupling and directly stimulates soluble guanylate cyclase, increasing the
production of cyclic guanosine monophosphate
(cGMP) and causing vasodilation [35]. In addition
it acts in synergy with NO to produce anti-aggregatory, anti-proliferative and vasodilatory effects
[36, 37] by increasing the concentrations of cGMP.
The PATENT-1 Trial was a phase 3, double
blinded study that riociguat improved the 6-minute walk distance both in naïve patients and
patents who were also on in those who were
receiving ERAs or prostanoids (+30 m in the
2.5 mg-maximum group and had decreased by a
mean of 6 m in the placebo group (least-squares
mean difference, 36 m; 95% confidence interval,
20 to 52; P < 0.001). There were significant improvements in pulmonary vascular resistance,
NT-proBNP levels, WHO functional class, time to
clinical worsening, and Borg dyspnea score [38].
Generally riociguat is well tolerated with the most
common side effects are headache and dizziness
which has been seen in up to one quarter of patients. Other common side effects include upset
stomach, leg swelling, runny nose and nausea.
Syncope was only seen one percent of patients. It
is important to note that riociguat is metabolized
thought the cytochrome p450 pathway, most specifically CYP1A1. For these reason patients who
smoke may require increased dosages due to fact

that CYP1A1 is inducible by chemicals found in
cigarette smoke [39]. In addition riociguat is the
only drug that has been approved for the treatment of WHO Group IV chronic thromboembolic
pulmonary hypertension (CTEPH) [40]. For the
treatment of WHO FC II and III, the ERS guidelines give a IB Class-Level recommendation and for
WHO FC IV patients a IIb-C recommendation [3].

Combination therapy

With the presence of multiple pathways at
play in the treat of PAH, the possibility to use
a more than one medication exists. It is known
that up to 36% of patients receive combinations
therapy and up to 9% receive triple therapy [41].
Initially it was the BREATHE-2 study, a randomized controlled trial that evaluated initial combination which failed to demonstrate any significant
advantage of initial combination of epoprostenol
and bosentan compared with epoprostenol alone
[42]. More recently though the AMBITION trial,
in which initial therapy with tadalafil and ambrisentan was found to be superior to monotherapy
and showed a 50% risk reduction in clinical
worsening and well as increased 6MWD and PAH
related hospitalizations [43]. However it is still
unclear if upfront combination therapy improves
long-term outcomes in comparison to sequential
add-on therapy in case of poor response to monotherapy. Recommendations have been outlined
in Table 10.
After initialization of PAH specific therapy
patients are reassesses in 3−6 months. Certain
parameters are taken into account to see if the
patient is responding to initiated medication.
Clinical response is based on patients overall
feeling, WHO functional class, exercise capacity, estimated echocardiogram pressures, 6MWD
amongst others. If clinical response is found to be
inadequate then addition of a second or tertiary
medication may be warranted. Meta-analysis of
data shows that combination therapy is beneficial
to patients [44]. Multiple studies have addressed
add-on combination therapy such as the STEP
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Table 10. Recommendations on the use Combination Therapy in PAH (adapted from Galie at al. [3])

Class and Level of Recommendation

Combination Therapy

WHO FC II

WHO FC III

References

WHO FC IV

I

B

I

B

IIb

C

[43]

Other ERA + PDE-5i

IIa

C

IIa

C

IIb

C

–

Bosentan + sildenafil + epoprostenol

–

–

IIa

C

IIa

C

[62]

Bosentan + epoprostenol

–

–

IIa

C

IIa

C

[63]

Ambrisentan + tadalafil

ERA — endothelin receptor antagonists; PDE-5i — phosphodiesterase 5 Inhibitors

Table 11. Recommendations on the use sequential Combination Therapy in PAH according to WHO FC (adapted from Galie
at al. [3])
Combination Therapy

Class and Level of Recommendation
WHO FC II

WHO FC III

References

WHO FC IV

Macitentan added to sildenafil

I

B

I

B

IIa

C

[30]

Riociguat added to bosentan

I

B

I

B

IIa

C

[38]

Selexipag* added to ERA and/or PDE-5i

I

B

I

B

IIa

C

[49, 50]

Sildenafil added to epoprostenol

–

–

I

B

IIa

B

[64]

Inhaled treprostinil added to sildenafil or bosentan

IIa

B

IIa

B

IIa

C

[18]

Inhaled iloprost added to bosentan

IIb

B

IIb

B

IIb

C

[45]

Tadalafil added to bosentan

IIa

C

IIa

C

IIa

C

[34]

Ambrisentan added to sildenafil

IIb

C

IIb

C

IIb

C

[65]

Bosentan added to epoprostenol

–

–

IIb

C

IIb

C

[66]

Bosentan added to sildenafil

IIb

C

IIb

C

IIB

C

[67, 68]

Sildenafil added to bosentan

IIb

C

IIb

C

IIb

C

[68]

Other double/triple combination

IIb

C

IIb

C

IIb

C

–

Riociguat added to sildenafil or other PDE-5i

III

B

III

B

III

B

[48]

*Not approved by European Medicine Agency (EMA) at time of ERS Guidelines publication [3]; ERA — endothelin receptor antagonist; PDE-5i — phosphodiesterase
5 inhibitors

study in which inhaled iloprost was added to
patients already on bosentan. Though a small
sample size, results of this study demonstrate
that the addition of inhaled iloprost in patients
with PAH with reduced exercise capacity on bosentan monotherapy is safe and efficacious (+26
m on 6MWT) [45]. Similarly The TRIUMP I study
showed that PAH patients who remain symptomatic on bosentan or sildenafil, the addition of
inhaled treprostinil improves exercise capacity
and quality of life and is safe and well-tolerated
[18]. As for other trials, it has been seen that the
addition of the ERA macitentan to pretreated
patients significantly delayed PAH related events
[30] and that addition of bosentan to sildenafil n
the COMPASS-2 trial improved exercise capacity
at week 16 but did not meet other primary endpoints [46]. The recommendations on efficacy of
56

sequential combination therapy set worth by the
ERS have been outlined in Table 11.

Drug interactions

With the majority of patient with severe PAH
being placed on combination therapy and evidence pointing towards initial combination therapy,
the use of multiple drugs working on multiple
pathways creates the possibility of drug-drug interactions and should be considered by physicians
when prescribing PAH specific therapy.
Clinicians must take some considerations
even in the setting of monotherapy. The PDE5 sildenafil is metabolized via the cytochrome
P450 pathway specifically involving CYP3A4 and
CYP2C9. There is an increase in sildenafil bioavailability and reduced clearance with CYP3A4
substrates and inhibitors and CYP3A4 substrates

www.pneumonologia.viamedica.pl

Sonu Sahni et al., Pulmonary arterial hypertension: a current review of pharmacological management

Table 12. Potential Interactions Between Pulmonary Arterial Hypertension-specific Medications for Concurrent Illnesses
Statins

Sulph.

RTIs

Protease
Inhibitors

Af

Cyclos.

Hormonal
Contraceptives

Epoprostenol

–

–

–

–

–

–

–

Treprostinil

–

–

–

–

–

–

–

Iloprost

–

–

–

–

–

–

–

Sildenafil

–

X

–

X

X

–

–

Tadalafil

–

X

–

X

X

–

–

X

X

–

X

X

X

–

Bosentan

X

X

X

X

X

X

X

Ambrisentan

–

–

–

X

–

X

–

Macitentan

–

–

–

X

–

X

–

Prostacyclin Analogues

Phosphodiesterase Type 5
Inhibitors

Soluble Guanylate Cyclase
Stimulators
Riociguat
Endothelin Receptor Antagonists

All data was obtained from FDA Drug Information Data; RTI — reverse transcriptase inhibitor; X — known interaction; – — no known interaction or not clinically
significant interaction; Cyclos — cyclosporine A; Barb — barbituates; Af — antifungals

plus beta-adrenoceptor blockers. Drugs that are
CYP3A4 inducers such as barbiturates, rifampicin
and St John’s wort may lower sildenafil levels and
should be used with caution. Sildenafil levels are
modestly increased by fresh grapefruit juice, a
weak inhibitor of CYP3A4 [3].
The ERA bosentan is an inducer of cytochrome P450 isoenzymes CYP3A4 and CYP2C9.
Plasma concentrations of drugs metabolized by
these isoenzymes will be reduced when co-administered with bosentan. Of note is that the
combination of a potent CYP3A4 inhibitor (ketoconazole, ritonavir) and/or a CYP2C9 inhibitor
(e.g. amiodarone, fluconazole) with bosentan may
cause a significant increase in plasma bosentan
levels and thus is contraindicated. Interactions
may theoretically occur with certain antifungals
as well as immunosuppressive drugs. An outline
of PAH specific medications and interactions with
commonly used drugs is shown in Table 12.
Now with PAH specific combination therapy
becoming commonplace there are a few important
therapeutic combinations that should be avoided.
The use of ERA bosentan with PDE-5 sildenafil
has been shown to significantly decrease plasma
concentrations of sildenafil [47]. In addition the
PATENT PLUS trial studied the effect of adding
the soluble guanylate cyclase stimulator, riociguat
to background sildenafil therapy which concluded
that riociguat in combination with sildenafil was

associated with high rates of discontinuation due
to hypotension, SAEs and deaths [48]. Therefore
concomitant use of riociguat with PDE-5 inhibitors (such as sildenafil, tadalafil and vardenafil) is
contraindicated. Common dosing of medications
has been presented in Table 13.

Future medications

As the vascular wall remain the primary
target in PAH specific drugs, new medications
focus on these biological pathways. The majority
of current therapeutic research is focused on the
prostacyclin and nitric oxide pathways. Selexipag
is an oral, selective prostacyclin receptor agonist
which is currently awaiting approval of the FDA.
In a proof of concept study by Simonneau et al.
it has been found that Selexipag use in patients
already receiving ERA or PDE-5 therapy, resulted
in a 30.3% reduction in mean pulmonary vascular
resistance versus placebo and systemic vascular
resistance along with an increase in cardiac index
[49]. The formal results of the GRIPHON study,
a multicenter, double blinded, placebo controlled phase 3 study of 1156 show that selexipag
reduced the risk of mortality/morbidity events
vs. placebo by 40% and the treatment effect was
consistent across age, gender, etiology, baseline
FC and background PAH therapy sub-groups [50].
Though not yet approved by the EMA based on
the ERS guidelines a Class-Level recommendation
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Table 13. Pulmonary Arterial Hypertension Medications Dosing
Medication Class and typical drug dosing range

Adverse Effects

Phosphodiesterase Type-5 Inhibitors
Sildenafil
Oral: 5mg or 20 mg three times daily; separate dosing by 4–6 hrs
IV: 2.5-mg or 10-mg bolus three times daily

Epistaxis, headache, dyspepsia, flushing, insomnia, erythema,
dyspnea worsened, rhinitis, sinusitis, myalgia, pyrexia, paresthesia;
hypotension, vision or hearing loss, priapism, vaso-occlusive crisis

Tadalafil
40 mg once daily. CrCl 31–80 ml/min: initially 20mg once daily,
increase to 40 mg once daily if tolerated. CrCl < 30 ml/min: not
recommended

Headache, myalgia, nasopharyngitis, flushing, respiratory tract
infection, pain, nausea, dyspepsia, sinus congestion; hypotension,
sudden vision or hearing loss, priapism, prolonged erection

Soluble Guanylate Cyclase (sGC) Stimulator
Riociguat
0.5−2.5 mg daily in three divided

Hypotension (low blood pressure), headache, and gastrointestinal
disorders

Endothelin Receptor Antagonists
Ambrisentan
5−10 mg daily

Peripheral edema, nasal congestion, sinusitis, flushing, elevated liver
enzymes; decreased sperm counts, hematologic changes

Bosentan
< 40 kg: 62.5 mg twice daily. > 40 kg: Initially 62.5 mg twice daily
for 4 weeks, then 125 mg twice daily. Take in the AM and PM

Hepatotoxicity, respiratory tract infection, headache, edema, chest
pain, syncope, flushing, hypotension, sinusitis, arthralgia, elevated
liver enzymes, palpitations, anemia; decreased sperm counts

Macitentan
10 mg once daily

Hepatotoxicity, Anemia, lightheadedness, headache, urinary tract
infection

Prostacyclin Analogues
Treprostinil
IV/SQ: 1−10 mg/ml for infusion.
Oral − 0.125 mg, 0.25 mg, 1 mg, 2.5 mg twice daily, titrating up.
Inhaled − 1.74 mg in 2.9 ml inhalation. 3 breaths of treprostinil per
treatment session, 4 times daily

Infusion reactions/site pain, headache, diarrhea, nausea, jaw pain,
vasodilatation, dizziness, edema, pruritus, hypotension

Epoprostenol
IV: 2 nanograms/kg per min; increase in increments of 2 nanograms/
kg per min at ≥ 15 minute intervals until response achieved or tolerance develops

Headache, jaw pain, flushing, GI upset, flu-like symptoms, anxiety,
dizziness, tachycardia, myalgia

Iloprost
10 mcg/ml, 20 mcg/ml; soln for inhalation using I-neb six to nine
times daily (no more than every 2 hours)
IV: 1 mg/ml for infusion

Vasodilation, increased cough, headache, lockjaw, insomnia, GI
upset, hypotension, flu syndrome, back pain, increased GGT, alkaline
phosphatase, tongue pain, palpitations, syncope, muscle cramps,
hemoptysis, pneumonia, CHF, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, kidney failure

*All data was obtained from FDA Drug Information Data

of I-B has been given for both WHO FC II and III
patients [3].
Another drug under investigation is Vardenafil, which is considered a PDE-5 inhibitor. It
differs from already marketed PDE-5 inhibitors by
having a short effective time and slight longer half
life than that of sildenafil. The EVALUATION study by Jing et al., which sought out to demonstrate
safety and efficacy of Vardenafil showed that it is
well tolerated in twice daily dosing and showed a
increase in 6MWD, and cardiac index, along with
an decrease in mean pulmonary arterial pressure
and pulmonary vascular resistance [51]. Though
not yet approved by the EMA based on the ERS
guidelines a Class-Level recommendation of IIbB
has been given for both WHO FC II and III patients
58

and a recommendation of IIb-C for WHO FC IV
patients [3].
In addition to traditional pathways a new
class of drug exists. Bardoxolone methyl is an
Nrf2 activator and NF-kB suppressor that targets
dysfunctional inflammatory, metabolic, and
bioenergetic pathways and is thought to have
beneficial effects on endothelial dysfunction,
as well as anti-proliferative and anti-fibrotic
effects [52]. The LARIAT trail is a phase 2,
dose-ranging, randomized, placebo-controlled,
double-blind trial to assess exercise capacity and
safety in patients taking stable PAH background
therapy. Initial results showed bardoxolone
methyl significantly increased placebo-corrected 6MWD in PAH patients on background oral
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PAH therapies and was well-tolerated at doses
up to 10 mg [53].
There have also been exploratory studies
into three pathways different than the ones mentioned above with unsatisfactory results using
the following compounds: inhaled vasoactive
intestinal peptide, tyrosine kinase inhibitors
(platelet-derived growth factor inhibitors) and
serotonin antagonists [3]. These drug compounds
should be avoided.

Non pharmacological considerations
As there is presently no cure for PAH, in addition to these pharmaceutical options, supervised exercise training should be considered [54].
It has been shown to increase exercise capacity,
WHO functional class, peak oxygen consumption
and resting heart rate [55, 56]. It has also been
observed that exercise may improve health related quality of life (HRQoL) [30], depression and
fatigue [57] which are all important in the overall
well being of the patient. Nevertheless excessive
physical activity leading to distressing symptoms
is not recommended in PAH patients.
PAH specific therapy has reduced and delayed patient referral for lung transplant but it
remains an important option for non-responders
to therapy [58]. The outcome of medically treated
patients is not always clear. Lung transplantation should continue to be an important option
for those who fail on PAH specific therapy and
remain in WHO-FC III or IV as it is for patients
who have PHTN in the setting of interstitial lung
disease [59].
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